Somatic augmentation strategies in clozapine resistance - What facts?

Clinical Neuropharmacology

Volumn 29, Issue 1, 2006, Pages 34-44

  Tranulis, Constantin ^a   Mouaffak, Fayçal ^b   Chouchana, Laurent ^b   Stip, Emmanuel ^a,c   Gourevitch, Raphael ^b   Poirier, Marie France ^b   Olié, Jean Pierre ^b   Lôo, Henri ^b   Gourion, David ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Antidepressant; Augmentation; Clozapine resistance; Electroconvulsive therapy; Fatty acids supplements; Glutamatergic agents; Mood stabilizer; Repetitive transcranial magnetic stimulation; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CYCLOSERINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; ICOSAPENTAENOIC ACID ETHYL ESTER; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PAROXETINE; POLYUNSATURATED FATTY ACID; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; VALPROIC ACID;

ATAXIA; AUDITORY HALLUCINATION; BIPOLAR DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS DISORDER; COORDINATION DISORDER; DELIRIUM; DEPRESSION; DIABETIC KETOACIDOSIS; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INTOXICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; ENURESIS; EPILEPSY; FAT INTAKE; FATIGUE; FLAPPING TREMOR; GRAND MAL SEIZURE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; HYPERSALIVATION; HYPERTENSION; LETHARGY; LEUKOPENIA; LIVER FUNCTION TEST; MEDICAL LITERATURE; MENTAL DISEASE; MOOD DISORDER; MYOCLONUS; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NEUTROPHILIA; ORTHOSTATIC HYPOTENSION; PANCYTOPENIA; POLYURIA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SINUS TACHYCARDIA; SLURRED SPEECH; STANDING; STEVENS JOHNSON SYNDROME; SUPRAVENTRICULAR TACHYCARDIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; DRUG RESISTANCE; POLYPHARMACY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DRUG RESISTANCE; DRUG SYNERGISM; ELECTROCONVULSIVE THERAPY; HUMANS; MENTAL DISORDERS; POLYPHARMACY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 33646357773     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200601000-00010     Document Type: Review

References (139)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
2. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. Suppl 1994;(25):18-21.
3. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27(4):615-628.
4. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry. 1994;55(2):44-49.
5. Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother. 2004;5(10):2053-2058.
6. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005;72(2-3):225-234.
7. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol. 2005;19(3):301-305.
8. Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol. 2003;18(6):305-313.
9. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106(5):323-330.
10. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43(Suppl 2):37-44.
11. Chong SA, Remington GJ, Bezchlibnyk-Butler KZ. Effect of clozapine on polypharmacy. Psychiatr Serv. 2000;51(2):250-252.
12. Kupchik M, Spivak B, Mester R, et al. Combined electroconvulsive- clozapine therapy. Clin Neuropharmacol. 2000;23(1):14-16.
13. Kales HC, Dequardo JR, Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23(3):547-556.
14. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry. 1997;171:109-112.
15. Kando JC, Tohen M, Castillo J, et al. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry. 1994;55(6):255-257.
16. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry. 1994;39(4):236-238.
17. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol. 2005;28(1):50-53.
18. Chong SA, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull. 2000;26(2):421-440.
19. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry. 1999;60(Suppl 23):14-19.
20. Naber D. Optimizing clozapine treatment. J Clin Psychiatry. 1999;60(Suppl 12):35-38.
21. Sharif ZA. Treatment refractory schizophrenia: how should we proceed? Psychiatr Q. 1998;69(4):263-281.
22. Barnes TR, McEvedy CJ, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry. 1996; Suppl(31):31-40.
23. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry. 2005;20(5-6):409-415.
24. Wilson WH. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry. 1995;37(2):132-133.
25. Facciola G, Avenoso A, Scordo MG, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit. 1999;21(3):341-345.
26. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994;151(1):123-125.
27. Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol. 1995;15(2):139-141.
28. Madeb R, Hirschmann S, Kurs R, et al. Combined clozapine and valproic acid treatment-induced agranulocytosis. Eur Psychiatry. 2002;17(4):238-239.
29. Pantelis C, Adesanya A. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatry. 2001;35(4):544-545.
30. Imbarlina MJ, Sarkar S, Marwah S, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatry. 2004;19(8):506-509.
31. Senechal A, Landry P, Deschamps R, et al. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale. 2002;28(6 Pt 1):567-569.
32. Wirshing WC, Ames D, Bisheff S, et al. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol. 1997;17(2):120-121.
33. Nicolai J, Smith SJ, Keunen RW. Simultaneous side effects of both clozapine and valproate. Intensive Care Med. 2001;27(5):943.
34. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47(2):332-372.
35. Gerson SL, Lieberman JA, Friedenberg WR, et al. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet. 1991;338(8761):262-263.
36. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet. 1988;2(8626-8627):1500.
37. Rittmannsberger H, Leblhuber F. Asterixis induced by carbamazepine therapy. Biol Psychiatry. 1992;32(4):364-368.
38. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003; 64(Suppl 12):5-19.
39. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995;28(1):26-28.
40. Jablonowski K, Margolese HC, Chouinard G. Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatry. 2002;47(10):975-976.
41. Usiskin SI, Nicolson R, Lenane M, et al. Gabapentin prophylaxis of clozapine-induced seizures. Am J Psychiatry. 2000;157(3):482-483.
42. Landry P. Gabapentin for clozapine-related seizures. Am J Psychiatry. 2001;158(11):1930-1931.
43. Kolivakis TT, Margolese HC, Beauclair L, et al. Clozapine for first-episode schizophrenia. Am J Psychiatry. 2002;159(2):317.
44. Papetti F, Darcourt G, Giordana JY, et al. Treatment of clozapine-induced granulocytopenia with lithium (two observations). Encephale. 2004;30(6):578-582.
45. Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol. 1998;18(1):86-88.
46. Adityanjee MD. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry. 1995;152(4):648-649.
47. Valevski A, Modai I, Lahav M, et al. Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol. 1993;8(1):63-65.
48. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol. 2003;13(3):401-404.
49. Rothstein G, Clarkson DR, Larsen W, et al. Effect of lithium on neutrophil mass and production. N Engl J Med. 1978;298(4):178-180.
50. Hellwig B, Hesslinger B, Walden J. Acute brain syndrome after tapering off clozapine in clozapine-lithium combination. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(1):179-183.
51. Small JG, Klapper MH, Malloy FW, et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2003;23(3):223-228.
52. Bender S, Linka T, Wolstein J, et al. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol. 2004;7(1):59-63.
53. Bryois C, Ferrero F. Clinical observation of 11 patients under clozapine-lithium association. Eur Psychiatry. 1993;8:213-218.
54. Garcia G, Crismon ML, Dorson PG. Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol. 1994;14(6):426-428.
55. Lee SH, Yang YY. Reversible neurotoxicity induced by a combination of clozapine and lithium: a case report. Zhonghua Yi Xue Za Zhi (Taipei). 1999;62(3):184-187.
56. Lemus CZ, Lieberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry. 1989;11(2):127-130.
57. Pope Jr HG , Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis. 174(8):1986;493-495.
58. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment. Am J Psychiatry. 1996;153(5):737-738.
59. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry. 1994;151(10):1520-1521.
60. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003;54(11):1241-1248.
61. Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine. Am J Psychiatry. 2001;158(11):1930.
62. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol. 2001;15(4):297-301.
63. Saba G, Dumortier G, Kalalou K, et al. Lamotrigine-clozapine combination in refractory schizophrenia: three cases. J Neuropsychiatry Clin Neurosci. 2002;14(1):86.
64. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000;45(2):198.
65. Navarro V, Pons A, Romero A, et al. Topiramate for clozapine-induced seizures. Am J Psychiatry. 2001;158(6):968-969.
66. Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry. 2003;64(10):1267-1268.
67. Millson RC, Owen JA, Lorberg GW, et al. Topiramate for refractory schizophrenia. Am J Psychiatry. 2002;159(4):675.
68. Behar D, Schaller JL. Topiramate leukopenia on clozapine. Eur Child Adolesc Psychiatry. 2004;13(1):51-52.
69. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in reatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005;66(8):1012-1015.
70. Husni M, Haggarty J, Peat C. Clozapine does not increase ECT-seizure duration. Can J Psychiatry. 1999;44(2):190-191.
71. Cardwell BA, Nakai B. Seizure activity in combined clozapine and ECT: a retrospective view. Convuls Ther. 1995;11(2):110-113.
72. Kupchik M, Spivak B, Mester R, et al. Combined electroconvulsive- clozapine therapy. Clin Neuropharmacol. 2000;23(1):14-16.
73. Bhatia SC, Bhatia SK, Gupta S. Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatment-resistant schizophrenia. J ECT. 1998;14(4):280-283.
74. Chanpattana W. Combined ECT and clozapine in treatment-resistant mania. J ECT. 2000;16(2):204-207.
75. Kales HC, Dequardo JR, Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23(3):547-556.
76. James DV, Gray NS. Elective combined electroconvulsive and clozapine therapy. Int Clin Psychopharmacol. 1999;14(2):69-72.
77. Kho KH, Blansjaar BA, de Vries S, et al. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia - an open label study. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):372-379.
78. Sienaert P, Bouckaert F, Fernandez I, et al. Propofol in the management of postictal delirium with clozapine-electroconvulsive therapy combination. J ECT. 2004;20(4):254-257.
79. Bloch Y, Pollack M, Mor I. Should the administration of ECT during clozapine therapy be contraindicated?[see comment][comment]. Br J Psychiatry. 1996;169(2):253-254.
80. Beale MD, Pritchett JT, Kellner CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther. 10(3):1994;228-231.
81. Klapheke MM. Clozapine, ECT, and schizoaffective disorder, bipolar type. Convuls Ther. 1991;7(1):36-39.
82. Landy DA. Combined use of clozapine and electroconvulsive therapy. Convuls Ther. 1991;7(3):218-221.
83. Safferman AZ, Munne R. Combining clozapine with ECT. Convuls Ther. 1992;8(2):141-143.
84. Masiar SJ, Johns CA. ECT following clozapine. Br J Psychiatry. 1991;158:135-136.
85. Fink M. ECT is an effective, but ignored, treatment of psychosis. Focus on antipsychotics. B. Green. Liverpool: University of Liverpool; 2004.
86. Frankenburg FR, Suppes T, McLean PE. Combined clozapine and electroconvulsive therapy. Convuls Ther. 1993;9(3):176-180.
87. Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93(2):137-143.
88. Green AI, Zalma A, Berman I, et al. Clozapine following ECT: a two-step treatment. J Clin Psychiatry. 1994; 55(9):388-390.
89. Rosa MA, Odebrecht M, Rigonatti SP, et al. Transcranial magnetic stimulation: review of accidental seizures. Rev Bras Psiquiatr. 2004;26(2):131-134.
90. Anschel DJ, Pascual-Leone A, Holmes GL. Anti-kindling effect of slow repetitive transcranial magnetic stimulation in rats. Neurosci Lett. 2003;351(1):9-12.
91. Kinoshita M, Ikeda A, Begum T, et al. Low-frequency repetitive transcranial magnetic stimulation for seizure suppression in patients with extratemporal lobe epilepsy - a pilot study. Seizure. 14(6):2005;387-392.
92. d'Alfonso AA, Aleman A, Kessels RP, et al. Transcranial magnetic stimulation of left auditory cortex in patients with schizophrenia: effects on hallucinations and neurocognition. J Neuropsychiatry Clin Neurosci. 2002;14(1):77-79.
93. Franck N, Poulet E, Terra JL, et al. Left temporoparietal transcranial magnetic stimulation in treatment-resistant schizophrenia with verbal hallucinations. Psychiatry Res. 2003;120(1):107-109.
94. Hoffman RE, Boutros NN, Hu S, et al. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet. 2000;355(9209):1073-1075.
95. Hoffman RE, Hawkins KA, Gueorguieva R, et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry. 2003;60(1):49-56.
96. Hoffman RE, Boutros NN, Berman RM, et al. Transcranial magnetic stimulation of left temporoparietal cortex in three patients reporting hallucinated "voices". Biol Psychiatry. 1999;46(1):130-132.
97. Fitzgerald PB, Benitez J, Daskalakis JZ, et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J Clin Psychopharmacol. 2005;25(4):358-362.
98. Chibbaro G, Daniele M, Alagona G, et al. Repetitive transcranial magnetic stimulation in schizophrenic patients reporting auditory hallucinations. Neurosci Lett. 2005;383(1-2):54-57.
99. Lee SH, Kim W, Chung YC, et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. Neurosci Lett. 2005;376(3): 177-181.
100. Schonfeldt-Lecuona C, Gron G, Walter H, et al. Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. NeuroReport. 2004;15(10):1669-1673.
101. McIntosh AM, Semple D, Tasker K, et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Res. 2004;127(1-2):9-17.
102. Hoffman RE, Gueorguieva R, Hawkins KA, et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry. 2005;58(2):97-104.
103. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 1996;153(6):820-822.
104. Anghelescu I, Szegedi A, Schlegel S, et al. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol. 1998;8(4):315-320.
105. Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001;11(4):275-283.
106. Taylor D, Ellison Z, Ementon Shaw L, et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol. 1998;13(1):19-21.
107. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry. 1999;32(4):148-153.
108. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry. 2000;61(8):594-599.
109. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65(6):766-771.
110. Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry. 1996;40(7):671-674.
111. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry. 1996;153(12):1625-1627.
112. Zoccali R, Muscatello MR, Torre DL, et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res. 2003;48(4):411-414.
113. Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2004;19(2):71-76.
114. Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about schizophrenia? Arch Gen Psychiatry. 1999;56(1):13-17.
115. Evins AE, Amico E, Posever TA, et al. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002;56(1-2):19-23.
116. Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. [see comment]. Arch Gen Psychiatry. 1999;56(1):29-36.
117. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. [see comment]. Arch Gen Psychiatry. 1999;56(1):21-27.
118. Heresco-Levy U, Ermilov M, Lichtenberg P, et al. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55(2):165-171.
119. Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001;4(4):385-391.
120. Goff DC, Tsai G, Manoach DS, et al. D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153(12):1628-1630.
121. Tsai GE, Yang P, Chung LC, et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999;156(11):1822-1825.
122. Goff DC, Henderson DC, Evins AE, et al. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45(4):512-514.
123. Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 1999;156(1):145-147.
124. Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000;157(5):826-828.
125. Williams JB, Mallorga PJ, Jeffrey Conn P, et al. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res. 2004;71(1):103-112.
126. Schwieler L, Engberg G, Erhardt S. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse. 2004;52(2):114-122.
127. Evins AE, Amico ET, Shih V, et al. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm. 1997;104(6-7):761-766.
128. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 1998;30(3):193-208.
129. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 2000;42(1):7.
130. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36(1):7-18.
131. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002;159(9):1596-1598.
132. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158(12):2071-2074.
133. Faisal I, Lindenmayer JP, Taintor Z, et al. Clozapine-benzodiazepine interactions. J Clin Psychiatry. 1997;58(12):547-548.
134. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. 1991;324(11):746-754.
135. Grohmann R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology (Berl). 1989; 99(Suppl):S101-S104.
136. Sassim N, Grohmann R. Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry. 1988;21(6):306-307.
137. Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. Ann Clin Psychiatry. 1995;7(3):139-141.
138. Overall JE, AG, DR. The brief psychiatric rating scale. Psychological Reports. 1962;10:799-812.
139. Guy W. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology-Revised. Department of Health and Welfare. Rockville, MD: 1976, 218-222.